Branched-Chain Amino Acid Transamination Inhibition to Modulate Neurotransmitter Homeostasis

BCAT1/BCAT2 metabolomics market 42% proposed
Composite
40%
Novelty
45%
Feasibility
45%
Impact
45%
Mechanistic
50%
Druggability
50%
Safety
30%
Confidence
40%

Mechanistic description

Branched-Chain Amino Acid Transamination Inhibition to Modulate Neurotransmitter Homeostasis

Evidence for (4)

  • Metabolomic studies report elevated plasma BCAAs in AD patients, with decreased utilization in brain tissue

    PMID:30239921

  • BCAT1 expression is reduced in AD hippocampus, correlating with decreased glutamate recycling capacity

    PMID:25486095

  • BCAA supplementation paradoxically improves cognitive function in some aging studies

    PMID:28214415

  • Mouse model studies demonstrate that BCAT inhibition reduces glutamate-mediated excitotoxicity in stroke models

    PMID:25199829

Evidence against (4)

  • BCAA supplementation shows mixed cognitive effects in meta-analyses - larger trials fail to replicate cognitive benefits

    PMID:30189549

  • BCAT has dual functions - global inhibition could disrupt glutamate homeostasis unpredictably, causing excitotoxicity or synaptic failure

  • Brain BCAT activity is highly regulated by leucine which affects mTOR signaling - distinguishing BCAT-specific effects challenging

    PMID:28873279

  • Industry programs (Janssen) for BCAT inhibitors dropped due to unclear efficacy

Bayesian persona consensus

47% posterior support

1 signal · 0 for / 1 against · agreement 0%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.